EMA Authorised: Combivir (lamivudine;zidovudine) — ViiV Healthcare BV

View source ↗

Summary

EMA authorised Combivir (lamivudine and zidovudine) for HIV infections, confirming market approval by ViiV Healthcare BV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infections

Drugs mentioned

• COMBIVIR (Lamivudine and Zidovudine)

Snippet

Status: Authorised. Therapeutic area: HIV Infections. MAH: ViiV Healthcare BV. Decision date: 11/08/2022